However, in hematological neoplasms such as chronic lymphocytic leukemia, Hodgkin’s lymphoma and diffuse large B lymphoma, IL-9 is generally considered to promote tumor progression via its lymphocyte growth factor function [12–14]. This evidence concerns the gene IL9 and B-cell chronic lymphocytic leukemia.